Barclays PLC Boosts Holdings in Tarsus Pharmaceuticals, Inc.

Dec 24, 2024 · Barclays PLC lifted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 345.9% during the third quarter, according to the company in its most recent …

9%
OFF

Barclays PLC Boosts Holdings In Tarsus Pharmaceuticals, Inc.

2 weeks from now

Dec 24, 2024 · Barclays PLC lifted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 345.9% during the third quarter, according to the company in its most recent …

marketbeat.com

9%
OFF

Barclays PLC Grows Stock Position In Tarsus Pharmaceuticals, Inc ...

2 weeks from now

Dec 24, 2024 · Barclays PLC boosted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 345.9% during the 3rd quarter, according to the company …

defenseworld.net

$60.00
OFF

Tarsus Pharmaceuticals (TARS) Receives A Buy From Barclays

2 weeks from now

1 day ago · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), with a price target of $60.00. The …

businessinsider.com

$60.00
OFF

Barclays Reaffirms Their Buy Rating On Tarsus Pharmaceuticals …

2 weeks from now

Oct 28, 2024 · Barclays analyst Balaji Prasad maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares …

businessinsider.com

$60.00
OFF

Tarsus Pharmaceuticals (TARS) Gets A Buy From Barclays

2 weeks from now

Nov 13, 2024 · Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares …

businessinsider.com

$3.20
OFF

Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

2 weeks from now

3 days ago · Earnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($3.20) to ($1.43) per share. Price to Earnings Ratio vs. the Market. The P/E ratio of Tarsus …

marketbeat.com

6%
OFF

Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This An ... - Nasdaq

2 weeks from now

Oct 30, 2024 · Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number …

nasdaq.com

5%
OFF

Barclays PLC Grows Stock Position In Zentalis Pharmaceuticals, Inc ...

2 weeks from now

Jan 6, 2025 · Barclays PLC increased its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) by 18.5% in the 3rd quarter, according to its most recent 13F …

etfdailynews.com

7%
OFF

Barclays PLC Has $1.62 Million Stock Position In ARS …

2 weeks from now

4 days ago · Barclays PLC raised its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 189.7% during the third quarter, according to the company …

marketbeat.com

$5
OFF

Tarsus Pharmaceuticals (TARS) Gets A Buy From Barclays

2 weeks from now

May 8, 2024 · Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $5...

businessinsider.com

$3.39
OFF

Barclays PLC Has $3.39 Million Stake In Supernus Pharmaceuticals, …

2 weeks from now

Dec 24, 2024 · NASDAQ SUPN opened at $35.59 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37. The company has a 50 day moving …

etfdailynews.com

0%
OFF

Barclays PLC Grows Holdings In Phathom Pharmaceuticals, Inc.

2 weeks from now

Dec 31, 2024 · Barclays PLC boosted its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 366.0% in the 3rd quarter, according to the company in its …

defenseworld.net

7%
OFF

Barclays PLC Raises Stock Position In ARS Pharmaceuticals, Inc.

2 weeks from now

Dec 28, 2024 · Barclays PLC boosted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 189.7% during the third quarter, according to the company …

marketbeat.com

1%
OFF

Insider Selling: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) …

2 weeks from now

5 days ago · A number of hedge funds have recently bought and sold shares of AMRX. Barclays PLC boosted its position in Amneal Pharmaceuticals by 134.1% in the third quarter. Barclays …

insidertrades.com

3%
OFF

Barclays PLC Grows Stake In Supernus Pharmaceuticals, Inc

2 weeks from now

Dec 24, 2024 · Barclays PLC lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 88.3% in the third quarter, according to its most recent …

marketbeat.com

0%
OFF

Barclays PLC Grows Position In Arcus Biosciences, Inc ... - MarketBeat

2 weeks from now

Dec 28, 2024 · Barclays PLC boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 49.0% during the 3rd quarter, according to its most recent disclosure with …

marketbeat.com

FAQs about Barclays PLC Boosts Holdings in Tarsus Pharmaceuticals, Inc. Coupon?

Should you buy Tarsus pharmaceuticals (Tars – research report)?

Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares closed yesterday at $47.57. According to TipRanks, Prasad is a 3-star analyst with an average return of 3.0% and a 45.01% success rate. ...

Will Tarsus Pharmaceuticals post earnings per share in Q1 2024?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Research analysts at William Blair lifted their Q1 2024 earnings per share estimates for Tarsus Pharmaceuticals in a report released on Wednesday, April 17th. William Blair analyst T. Lugo now expects that the company will post earnings o ...

Does Barclays PLC own Supernus Pharmaceuticals?

Barclays PLC’s holdings in Supernus Pharmaceuticals were worth $3,393,000 as of its most recent SEC filing. Several other institutional investors and hedge funds have also recently bought and sold shares of the business. GAMMA Investing LLC lifted its holdings in shares of Supernus Pharmaceuticals by 97.1% during the 3rd quarter. ...

How much is Tarsus Pharmaceuticals stock now?

Tarsus Pharmaceuticals' stock was trading at $20.25 at the start of the year. Since then, TARS stock has increased by 163.0% and is now trading at $53.26. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) released its quarterly earnings data on Thursday, August, 8th. ...

Does vivo capital own Tarsus pharmaceuticals (Tars)?

Vivo Capital LLC trimmed its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 68.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 565,550 shares of the company's stock after selling 1,2 ...

How much did Tarsus pharmaceuticals raise in an IPO?

Tarsus Pharmaceuticals (TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. ...